Ticker: VTRS | Price: $8.76 (May 19, 2025, 4:00 PM ET) 💊 
Title Variant: Viatris: When Your CEO Buys Half a Million Dollars’ Worth, You Pay Attention... Right?

📢 Insider Trigger: Money Where His Mouth Is

Scott Smith, Viatris CEO, just scooped up 60,000 shares at $8.94 each—dropping $536,262 into his own company. That's not a tweet. That’s skin in the pharmaceutical game. 💉💰

🧠 He now holds over 292,000 shares, a 26% increase. Confidence, much?

🏢 Institutional Support: They’re In Too

85.64% of the float is held by institutions. These aren't your fantasy football buddies—these are the pros.

Top holders:

• Vanguard: 12.32%

• BlackRock: 8.27%

• T. Rowe Price: 6.34%

• Davis Selected Advisers: 5.53%

• State Street: 5.24%

🧳 That’s a Wall Street who’s who.

🔍 For full Institutional Ownership breakdown, see here

🧬 What Does Viatris Do Again?

• Born from the 2020 merger of Mylan and Upjohn (Pfizer).

• Global player in generics, branded meds, biosimilars, and active pharmaceutical ingredients (APIs).

• Motto: Access to medicine—because no one likes a $700 EpiPen.

📉 Earnings Recap: Q1 2025

🧾 Total Revenue: $3.3B
🔻 Down 11% YoY
💥 Blame: “The Indore Impact” (no, not a Marvel villain, just business headwinds)

🧠 Excluding that, revenues are up 2% on a divestiture-adjusted operational basis.

📊 Adjusted Financial Highlights

• Adjusted EBITDA: $923M (Down 23%)

• Adjusted EPS: $0.50 (Down 25%)

• Free Cash Flow: $493M

• Operating Cash Flow: $535M

• 💣 GAAP Net Loss: $(3.0)B

• 📉 Why? A non-cash goodwill impairment of $2.9B. Ouch, but paper cut.

💸 Shareholder love: Over $450M returned YTD

• $300M in buybacks

• $143M in dividends

• Forward dividend yield? 5.48% = sweet pill 💊💸

For more resources on Viatris's financial statements,
Check this out.

🔬 Pipeline Positivity

✅ 3 new positive Phase 3 readouts:

• EFFEXOR SR: Anxiety treatment seeking approval in Japan

• Meloxicam: Fast-acting pain relief—Phase 3 success

• XULANE LO™: New contraceptive patch, best-in-class potential

📅 NDAs planned for late 2025. Could be a launch party or a lab flop—but so far, data looks solid.

📦 Capital Allocation

Still confident. Still aggressive. Still paying you to wait.

🪙 2025 Capital Return Goals:

• $500M–$650M in buybacks

• Continue dividend payouts

• All while managing $14.2B in debt and $15.7B in equity

💣 Debt-to-equity ratio? 90.6%. But hey, they’ve got $1.0B in cash and a plan (hopefully).

💸 Valuation Talk: Is It Cheap?

• P/E Ratio (forward): Under 5

• Price: Near all-time lows

• Market Cap: Just $10B

For a company pulling in $3.3B per quarter, that’s either a value play—or a trap disguised as a bargain bin.

For another possible turnaround or contrarian play,
Check our take on UnitedHealth Group.

⚠️ Risks (a.k.a. Side Effects)

• 😬 Sales are stalling, at best.

• 😵 That $3B GAAP loss isn’t cosmetic.

• 🔬 Phase 3 ≠ guaranteed FDA greenlight

• 🏋️ Heavy debt load = fewer margin-for-error pills

• 🌍 Tariffs, global chaos, zombie apocalypse... the usual

🧠 Final Take: Is Viatris a Buy?

✅ CEO is buying.
✅ Institutional support is solid.
✅ Pipeline progress is encouraging.
✅ The stock looks cheap—and pays you to wait.

❌ Revenue growth is sluggish.
❌ Losses still sting.
❌ Debt isn’t small, and neither are expectations.

👟 If you’re going to buy, start small. Like aspirin—better as a preventative dose than a full-body replacement.

🧪 Funanc1al’s Verdict

🧬 Stability: ✅
💸 Income: ✅✅
📉 Growth: ❌ (For now)
🧠 Speculative Upside: ✅ (Pipeline could pop)
🤡 Humor Bonus: You’ll need it if goodwill gets impaired again.

❓ Disclaimer

We don’t sell pills. We don’t sell stocks either. Just fun, flair, and maybe a little financial glow-up. Invest at your own risk. Always.

🧭 Want More Like This?

👉 Browse our Insider Purchases Hub
👉 Or explore Turnaround Plays Section you might actually swipe right on